(S)-3-[4-[3-(2-Dimethylamino-ethyl)-ureido]-2-(2-quinolin-5-yl-ethoxy)-benzenesulfonylamino]-4-oxo-butyric acid | 475213-30-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: (S)-3-[4-[3-(2-Dimethylamino-ethyl)-ureido]-2-(2-quinolin-5-yl-ethoxy)-benzenesulfonylamino]-4-oxo-butyric acid
• 英文别名: (3S)-3-[[4-[2-(dimethylamino)ethylcarbamoylamino]-2-(2-quinolin-5-ylethoxy)phenyl]sulfonylamino]-4-oxobutanoic acid
• CAS: 475213-30-0
• 化学式: C₂₆H₃₁N₅O₇S
• 分子量: 557.627
• InChiKey: BAXYMWYAALWOHM-FQEVSTJZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  39
• 可旋转键数：
  14
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  175
• 氢给体数：
  4
• 氢受体数：
  10

文献信息

• Arylsulfonamide ethers, and methods of use thereof
  申请人：——

  公开号：US20030096826A1

  公开（公告）日：2003-05-22

  Novel arylsulfonamide ether compounds and pharmaceutical compositions thereof are described. The use of the novel arylsulfonamide ether compounds and pharmaceutical compositions thereof as inhibitors of interleukin-1&bgr; converting enzyme and other cysteine proteases in the ICE family is also decribed. In addition, methods of treating stroke, inflammatory diseases, septic shock, repurfusion injury, Alzheimer's disease, and shigellosis using a compound of the invention or a pharmaceutical composition thereof are described.

  描述了新型芳基磺酰胺醚化合物及其药物组合物。还描述了将这些新型芳基磺酰胺醚化合物和药物组合物用作干扰素γ转化酶和其他ICE家族半胱氨酸蛋白酶的抑制剂的用途。此外，还描述了使用本发明的化合物或其药物组合物治疗中风、炎症性疾病、脓毒性休克、再灌注损伤、阿尔茨海默病和志贺氏菌病的方法。
• ARYLSULFONAMIDE ETHERS, AND METHODS OF USE THEREOF
  申请人：Abbott GmbH & Co. KG

  公开号：EP1392280A2

  公开（公告）日：2004-03-03
• EP1392280A4
  申请人：——

  公开号：EP1392280A4

  公开（公告）日：2005-11-30
• US6875765B2
  申请人：——

  公开号：US6875765B2

  公开（公告）日：2005-04-05
• [EN] ARYLSULFONAMIDE ETHERS, AND METHODS OF USE THEREOF<br/>[FR] ETHERS ARYLSULFONAMIDE ET TECHNIQUES D'UTILISATION DE CES COMPOSES
  申请人：ABBOTT GMBH & CO KG

  公开号：WO2002089749A2

  公开（公告）日：2002-11-14

  Novel arylsulfonamide ether compounds and pharmaceutical compositions thereof are described. The use of the novel arylsulfonamide ether compounds and pharmaceutical compositions thereof as inhibitors of interleukin-1β converting enzyme and other cysteine proteases in the ICE family is also described. In addition, methods of treating stroke, inflammatory diseases, septic shock, repurfusion injury, Alzheimer's disease, and shigellosis using a compound of the invention or a pharmaceutical composition thereof are described.